Plant Name: Cinnamomum camphora
Taxonomic Information:
Plant ID: NPO6701
Plant Latin Name: Cinnamomum camphora
Taxonomy Genus: Cinnamomum
Taxonomy Family: Lauraceae
Plant External Links:
NCBI TaxonomyDB:
13429
Plant-of-the-World-Online:
463336-1
Used in Medicines:
Country/Region:
Madagascar; Indonesia; Angola; South Africa; India; Vietnam; Lebanon; Zimbabwe; Jordan; Swaziland; Thailand; ChinaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyMedicinal Functions:
Analgesic; Anthelmintic; Antianxiety; Antiarrhythmic; Antirheumatic; Antispasmodic; Aromatherapy; Cardiotonic; Carminative; Deodorant; Diaphoretic; Odontalgic; Rubefacient; Sedative; Stimulant; Tonic
Geographical Distribution:
Madagascar; Bangladesh; Guinea; Nepal; Cambodia; Swaziland; El Salvador; Zimbabwe; Jordan; Lebanon; China; Indonesia; Mauritius; Trinidad and Tobago; Vietnam; Thailand; Honduras; United States; Seychelles; Angola; South Africa; India; Japan; Taiwan; Fiji
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PRKCE; PRKCB; MAPK1; PRKCH; PRKCG; PRKCD; PRKCA; PRKCQ; | |
| TP53; | |
| MAPT; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | PRKCB | Protein kinase C beta | P05771 | CHEMBL3045 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PRKCH | Protein kinase C eta | P24723 | CHEMBL3616 |
| Protein Kinase | PRKCG | Protein kinase C gamma | P05129 | CHEMBL2938 |
| Protein Kinase | PRKCD | Protein kinase C delta | Q05655 | CHEMBL2996 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004699; calcium-independent protein kinase C activity | 1.832E-10 | 6.648E-07 | PRKCD, PRKCE, PRKCH |
| MF | GO:0003824; catalytic activity | GO:0004698; calcium-dependent protein kinase C activity | 7.325E-10 | 1.595E-06 | PRKCA, PRKCB, PRKCG |
| BP | GO:0009987; cellular process | GO:0034351; negative regulation of glial cell apoptotic process | 1.024E-08 | 1.487E-05 | PRKCA, PRKCD, PRKCH |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.554E-08 | 1.880E-05 | MAPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ, TP53 |
| BP | GO:0009987; cellular process | GO:0090330; regulation of platelet aggregation | 1.487E-07 | 8.751E-05 | PRKCA, PRKCD, PRKCQ |
| BP | GO:0008152; metabolic process | GO:0035408; histone H3-T6 phosphorylation | 3.538E-07 | 1.675E-04 | PRKCA, PRKCB |
| MF | GO:0003824; catalytic activity | GO:0035403; histone kinase activity (H3-T6 specific) | 3.538E-07 | 1.675E-04 | PRKCA, PRKCB |
| BP | GO:0050896; response to stimulus | GO:0046627; negative regulation of insulin receptor signaling pathway | 7.367E-07 | 2.814E-04 | PRKCB, PRKCD, PRKCQ |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 2.237E-06 | 6.375E-04 | LMNA, MAPK1, MAPT, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ, TP53 |
| BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 2.392E-06 | 6.676E-04 | LMNA, PRKCA, PRKCB |
| BP | GO:0009987; cellular process | GO:0050861; positive regulation of B cell receptor signaling pathway | 7.417E-06 | 1.568E-03 | PRKCB, PRKCH |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.558E-05 | 2.784E-03 | MAPK1, MAPT, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ, TSHR |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.007E-05 | 3.286E-03 | MAPK1, PRKCD, PRKCE, TP53 |
| BP | GO:0008152; metabolic process | GO:0032930; positive regulation of superoxide anion generation | 3.206E-05 | 4.738E-03 | MAPT, PRKCD |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.220E-05 | 4.738E-03 | LMNA, PRKCE, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.605E-05 | 5.131E-03 | MAPK1, PRKCD, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 4.787E-05 | 6.474E-03 | MAPK1, PRKCQ |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 4.938E-05 | 6.638E-03 | PRKCD, PRKCE, TP53 |
| BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 6.269E-05 | 8.125E-03 | MAPK1, PRKCD, PRKCE |
| BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 7.815E-05 | 9.402E-03 | PRKCB, PRKCH, PRKCQ |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.149E-14 | 8.340E-11 | MAPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09153 Circulatory system | hsa04270 | Vascular smooth muscle contraction | 6.430E-16 | 8.295E-14 | PRKCG, PRKCH, PRKCB, PRKCE, PRKCD, MAPK1, PRKCA, PRKCQ |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.233E-14 | 2.731E-12 | PRKCG, PRKCH, PRKCB, PRKCE, PRKCD, PRKCA, PRKCQ |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04530 | Tight junction | 5.174E-13 | 2.225E-11 | PRKCG, PRKCH, PRKCB, PRKCE, PRKCD, PRKCA, PRKCQ |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 7.754E-12 | 2.501E-10 | PRKCG, PRKCB, PRKCE, PRKCD, MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.118E-10 | 2.404E-09 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.412E-10 | 4.445E-09 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 3.690E-11 | 9.520E-10 | PRKCG, PRKCB, PRKCE, MAPK1, PRKCA, TP53 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.289E-09 | 3.690E-08 | PRKCB, PRKCE, PRKCD, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 3.511E-09 | 5.032E-08 | PRKCG, PRKCB, MAPK1, PRKCA, MAPT, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 5.030E-09 | 6.489E-08 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 8.742E-09 | 9.397E-08 | PRKCG, PRKCB, PRKCE, MAPK1, PRKCA, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.471E-08 | 1.460E-07 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 6.041E-09 | 7.084E-08 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.557E-08 | 3.059E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.666E-08 | 5.204E-07 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 3.806E-08 | 3.068E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 3.557E-08 | 3.059E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04925 | Aldosterone synthesis and secretion | 1.206E-07 | 7.776E-07 | PRKCG, PRKCB, PRKCE, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04720 | Long-term potentiation | 5.248E-08 | 3.982E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04918 | Thyroid hormone synthesis | 7.063E-08 | 5.062E-07 | PRKCG, PRKCB, PRKCA, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.610E-07 | 9.886E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.930E-07 | 1.083E-06 | PRKCB, PRKCD, MAPK1, PRKCA |
| 09150 Organismal Systems | 09159 Environmental adaptation | hsa04713 | Circadian entrainment | 2.297E-07 | 1.234E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 2.824E-07 | 1.404E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.686E-07 | 9.886E-07 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 2.940E-07 | 1.404E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.940E-07 | 1.404E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 4.298E-07 | 1.848E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.181E-07 | 1.466E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 3.995E-07 | 1.777E-06 | PRKCB, PRKCE, PRKCD, PRKCQ |
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 4.784E-07 | 1.929E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.456E-07 | 1.854E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.122E-06 | 7.398E-06 | PRKCG, PRKCB, MAPK1, PRKCA, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 9.424E-07 | 3.684E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.767E-06 | 6.331E-06 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.154E-06 | 4.252E-06 | PRKCG, PRKCB, PRKCA, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.578E-06 | 1.755E-05 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.693E-06 | 1.513E-05 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.449E-06 | 2.288E-05 | PRKCG, PRKCB, MAPK1, PRKCA |
| 09150 Organismal Systems | 09154 Digestive system | hsa04971 | Gastric acid secretion | 1.044E-05 | 3.062E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04911 | Insulin secretion | 1.585E-05 | 4.545E-05 | PRKCG, PRKCB, PRKCA |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 7.052E-05 | 1.654E-04 | LMNA, MAPK1, TP53 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 7.736E-06 | 2.321E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04727 | GABAergic synapse | 1.760E-05 | 4.935E-05 | PRKCG, PRKCB, PRKCA |
| 09160 Human Diseases | 09164 Substance dependence | hsa05032 | Morphine addiction | 1.946E-05 | 5.230E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09154 Digestive system | hsa04970 | Salivary secretion | 1.820E-05 | 4.996E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 4.455E-05 | 1.084E-04 | PRKCD, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 2.431E-05 | 6.271E-05 | PRKCG, PRKCB, PRKCA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.582E-05 | 6.532E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 5.527E-05 | 1.320E-04 | PRKCG, PRKCB, PRKCA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.367E-04 | 3.094E-04 | PRKCB, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.486E-04 | 3.305E-04 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09154 Digestive system | hsa04972 | Pancreatic secretion | 2.285E-05 | 6.015E-05 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 4.237E-05 | 1.051E-04 | PRKCG, PRKCB, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 1.663E-04 | 3.636E-04 | PRKCB, PRKCD, MAPK1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 2.636E-06 | 8.950E-06 | PRKCG, PRKCB, PRKCA |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 2.811E-06 | 9.299E-06 | PRKCE, PRKCD, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 9.641E-04 | 1.777E-03 | MAPK1, PRKCA, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.897E-03 | 4.918E-03 | PRKCQ, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 3.241E-03 | 5.429E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.773E-03 | 4.770E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.419E-03 | 5.655E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 4.330E-03 | 7.063E-03 | PRKCE, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.089E-03 | 9.697E-03 | MAPK1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.550E-03 | 2.739E-03 | PRKCD, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05143 | African trypanosomiasis | 1.068E-06 | 4.054E-06 | PRKCG, PRKCB, PRKCA |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 4.380E-03 | 7.063E-03 | MAPK1, MAPT |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.708E-03 | 2.978E-03 | MAPK1, PRKCQ |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.255E-03 | 2.281E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 7.354E-04 | 1.460E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 8.470E-04 | 1.584E-03 | PRKCB, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.370E-03 | 2.454E-03 | PRKCB, PRKCQ |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.014E-04 | 1.566E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 6.929E-04 | 1.419E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 8.470E-04 | 1.584E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.140E-04 | 1.439E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 8.470E-04 | 1.584E-03 | PRKCB, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 6.117E-04 | 1.273E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.304E-04 | 9.101E-04 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.671E-04 | 5.743E-04 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.328E-04 | 3.059E-04 | MAPK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| C00-D49: Neoplasms | Central nervous system tumors | NA | PRKCB; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | PRKCB; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; PRKCB; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | PRKCB; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PRKCQ; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| I00-I99: Diseases of the circulatory system | Acute myocardial infarction | I21-I22 | PRKCD; |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | PRKCB; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | PRKCB; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | PRKCE; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| NA: NA | Reperfusion injury and heart attacks | NA | PRKCD; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PRKCB; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
